Contrasting Absci (NASDAQ:ABSI) and Legend Biotech (NASDAQ:LEGN)

Legend Biotech (NASDAQ:LEGN) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Profitability

This table compares Legend Biotech and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Absci	-7,756.38%	-61.71%	-54.52%

Earnings and Valuation

This table compares Legend Biotech and Absci”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03 billion	4.05	-$296.80 million	($0.25)	-86.08
Absci	$2.80 million	540.57	-$115.18 million	($0.80)	-11.03

Absci has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Legend Biotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Legend Biotech and Absci, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1	6	8	0	2.47
Absci	1	0	8	0	2.78

Legend Biotech presently has a consensus target price of $53.43, indicating a potential upside of 148.27%. Absci has a consensus target price of $13.43, indicating a potential upside of 52.25%. Given Legend Biotech’s higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Absci.

Summary

Legend Biotech beats Absci on 7 of the 13 factors compared between the two stocks.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.